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Background: The aim of the trial was to evaluate the effectiveness of a program
of cooperation between physician and pharmacist to reduce cardiovascular risk factors
in patients with mild to moderate hypertension by promoting better blood pressure
(BP) control, appropriate changes in antihypertensive medications, and beneficial30
changes in lifestyle.
Methods: The 132 subjects in this randomized, controlled trial were in the age
range of 40–79 years. The inclusion criteria were: systolic BP (SBP) ranging from
140–179 mm Hg and/or diastolic BP (DBP) ranging from 90-99 mm Hg and
treatment-naive (untreated for hypertension); or on a regimen of medication for35
hypertension. Of these 132 subjects, 124 (94%) were already receiving treatment with
antihypertensive medications. Equal numbers of subjects were randomly assigned
to one of two groups: a physician–pharmacist intervention group (n = 66) and a
control group (n = 66).
Results: The 6-month follow-up rate was 97% in both groups. At 6 months, the40
mean decrease in SBP/DBP, as measured at home in the morning, was
2.9/3.3 mm Hg in the intervention group relative to baseline (P = 0.02
and P <0.0001 for SBP and DBP, respectively). The mean decrease in home morning
SBP in the intervention group was not significantly greater than in the control group.
However, this was a significantly greater decline than in the control group, which45
showed a mean decrease of 2.8 mm Hg in home morning DBP (confidence interval: –
5.5 to –0.1; P = 0.04). The percentage of patients in whom control of home morning
BP was achieved was 53% in the intervention group and 47% in the control group (P
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= 0.40). A higher percentage of patients in the intervention group, relative to the
control group,50
were able to reduce the use of antihypertensive medications (31 vs. 8%, P <0.0001),
and fewer patients in this group required additional medications or increases in dosage
relative to the controls (11 vs. 28%, P = 0.03). Patients of the intervention group were
more likely to show reduction in body mass index and sodium intake and to stop
smoking, as compared with the control group.55
Conclusions: A program of cooperation between physician and pharmacist was
successful in reducing cardiovascular risk factors in patients with mild to moderate
hypertension by promoting better blood pressure (BP) control, appropriate changes in
antihypertensive medications, and beneficial changes in lifestyle.
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Introduction60
Despite major advances in pharmacological treatment, hypertension is an increasingly
common health problem worldwide.1 Blood pressure (BP) control in patients on
antihypertensive medication has been evaluated as unsatisfactory in the United
States, Canada, and other European countries.2 In Japan, it was estimated that, in the65
year 2008, 39 million people had hypertension (i.e., nearly 38% of the adult
population), almost half of them were untreated,3 and the control of hypertension in
~50% of those on antihypertensive medication was not satisfactory.4
Recent meta-analyses have demonstrated that team-based care involving a
pharmacist can improve hypertension control.5 Most physician–pharmacist70
comanagement programs are designed to provide a clinically satisfactory control of
BP in patients through the addition/substitution of suitable medications, titration of
dosages, and/or enhancement of adherence to therapy.6–8 Although lifestyle
modifications are known to enhance the antihypertensive effects of medications and
help to reduce the required dosage of drugs,9 the programs described did not focus on75
this issue. Pharmacist-based medication counseling, including counseling regarding
lifestyle modification, could contribute to reductions in both the number and dosage of
antihypertensive agents; however, this needs to be confirmed by a thorough analysis.
We conducted a randomized-controlled trial to test the a priori hypothesis that
physician–pharmacist cooperation can reduce antihypertensive medication use and80
cardiovascular risk factors in patients with mild to moderate hypertension by
improving BP control, providing advice on appropriate changes in antihypertensive
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medication regimens and offering intensive counseling regarding beneficial lifestyle
modifications.
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Methods85
Setting
This 6-month randomized-controlled trial for hypertension control was conducted at a
community-based primary care center, Miho Medical Clinic, located in Ibaraki
Prefecture, Japan, which had ~2,000 outpatient visits each month during the fiscal90
year 2007.
Participants and recruitment
Figure 1 provides a flow chart of the recruitment process of patients
participating in this study. The study subjects were 412 patients with hypertension
who visited the Miho Medical Clinic between April 2007 and June 2007. Enrollment95
in the study began on 1 July 2007 and was completed on 30 September 2007. The
eligible participants were men and women 40–79 years of age, either taking
antihypertensive medications under a stable regimen or treatment naive and with a
systolic BP (SBP) of 140–179 mm Hg and/or diastolic BP (DBP) of 90–109 mm Hg,
as determined at two or more occasions during the recruitment period. On the basis of100
medical records, we excluded patients with a history of cardiovascular disease (stroke,
transient ischemic attack, coronary heart disease, or heart failure), rheumatoid arthritis,
endocrine diseases, and diabetes mellitus requiring medications, all of which usually
require aggressive BP control. Patients on exercise restriction (>20-min brisk walking
or cycling per day) as identified after a face-to-face interview with a physician,105
were also excluded. We also excluded patients with secondary hypertension, as
diagnosed by a physician on the basis of the clinical history, physical examination,
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and if appropriate, laboratory tests of the patients. None of the patients had renal
dysfunction (defined as serum creatinine ≥2.0 mg/dl) or was on regular treatment with 
nonsteroidal anti-inflammatory drugs. The study was approved by University of110
Tsukuba and Osaka University Ethics Committees, and written informed consent
was obtained from each patient before enrollment.
Physician–pharmacist program of cooperation
After a 1-month run-in period, the participants were randomized into the intervention
or control group in a 1:1 ratio, using a computer-generated random number sequence115
provided by a statistician who had no contact with the participants. The randomization
assignment details were revealed to participants as well as study personnel only after
the completion of baseline data collection. The study team comprised five physicians
and a pharmacist who had been trained to measure office BP in accordance with the
Japanese Society of Hypertension Guidelines for the Management of Hypertension120
(JSH 2004),10 and all the personnel adhered to the study protocol. The pharmacist
had worked in the clinic for >10 years and had participated in research activities
involving provision of health services at Tsukuba University.
In the first 20 min of the first session, printed educational leaflets about
treatment of hypertension were distributed to the participants. The intervention group125
received subsequent 15-min sessions of monthly individual counseling for 6 months
(Table 1). On the basis of each patient’s baseline data, including responses to lifestyle
questionnaires,11,12 the pharmacist met with each patient separately in the first session
to set up individual goals. At each visit, depending on the predetermined
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protocol, the pharmacist offered the patient bold messages 11 which translated into130
individual goals, e.g., restriction of miso soup to one bowl or less per day, and
reducing the size of the evening meal. Patients with body mass index (BMI)
≥25 kg/m2 and those who walked <30 min/day, were advised to record their body
weights and total duration of physical activity on a daily basis. On the basis of the
patients’ BP data, the pharmacist also offered physicians the following135
recommendations, as appropriate: reduction of drug dose by one-half or
discontinuation of drug for patients who achieved the target BP; switching of the
timing of medication, most often from wake-up time to bedtime, addition of a
different class of drug, or increase in drug dose for patients who did not achieve
target BP; and change in drug class for patients who had side effects or did not140
respond to treatment. The pharmacist offered physicians a choice of drugs that could
be prescribed for the patients: α-adrenergic antagonists and/or β-blockers as tapering 
drugs, and angiotensin-converting enzyme inhibitors, calcium channel blockers,
and/or low-dose diuretics as added drugs. The pharmacist attached counseling reports
and recommendations about those medication changes and downloaded the home BP145
data into the patients’ medical record as feedback to the physician. The physicians
constructed a treatment plan, taking into account the pharmacist’s recommendations,
based on the JSH 2004.10 The physicians discussed the treatment plan with the
pharmacist over the telephone, or face-to-face if necessary, during the examination of
the patient.150
The follow-up protocol for patients of the control group was similar to that for
the intervention group, but the pharmacist’s monthly sessions and reports to the
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physician were omitted (Table 1). Adherence to medication was evaluated by pill
counts and the prescription refills at each visit, and expressed as
a percentage of the predicted dose. For ethical reasons, patients in the control group155
were given the same counseling sessions in the 6 months after the end of the
intervention period.
Outcomes
1) Distribution of antihypertensive medications160
Physicians were instructed by the pharmacist to follow a standardized regimen
for all antihypertensive medications in both groups, modified where necessary only in
accordance with the JSH 2004 guidelines. This was done in order to eliminate bias
from unblinding of the groupwise assignment of patients. The target BP levels
were: office BP <130/85 mm Hg (<65 years) and <140/90 mm Hg (≥65 years) and 165
mean home BP <135/85 mm Hg. At each visit to the clinic during the study, the
average value of all available home BP logs was considered as mean home BP. We
considered only the morning BP logs in calculating the mean home BP when the mean
difference in the SBP readings between morning and evening was >15 mm Hg.13 In
order to attain the target BP levels, physicians prescribed antihypertensive drugs170
for both the intervention and control groups based on a standardized regimen (Figure
2). For the purpose of attaining better control of BP and/or avoid side effects,
changing medications and/or the timings of medication administration were carried
out throughout the trial as required.
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All recommendations regarding the prescription medications made by the175
pharmacist were approved by the physicians.
2) BP measurements
In accordance with the guidelines of JSH2004, both office and home BPs were
measured. Office BP represented the average of two readings taken by a physician180
using a mercury manometer after the participant had rested for 5 min in a seated
posture. When the difference in two consecutive SBP or DBP readings was >5 mm Hg,
another measurement was taken, and the office BP represented the average of
three readings. Office BP at baseline (August–October, 2007) was calculated as the
average of BP measurements on two separate visits taken before the randomization,185
and the average BP at the end of 6 months (April–May, 2008) was calculated as
the average of the measurements taken at two visits before the 6-month follow-up.
The home BP logs and readings were recorded using automatic validated
oscillometric manometers UA-767PC (A and D, Tokyo, Japan),14 certified by the
British Hypertension Society. The pharmacist and the physicians were blinded with190
respect to home BP measurements. The pharmacist trained all the patients at the time
of enrollment to use the device appropriately to measure BP, with a special emphasis
on keeping the arm-cuff at heart level, and extending and relaxing the arm using a
supporting pillow. Measurements were taken twice daily after 2 min of rest in a seated
position with feet flat on the floor, once within 1 h after waking up in the morning and195
the other just before bedtime. If the participants took two or more BP measurements at
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each of the two indicated time periods, the first reading was used for the analysis.
These procedures were followed in every instance, and have been described in
detail previously.15 All the patients were also advised to record in writing the BP
readings at the time of measurement of BP using the automated device. Measurements200
taken outside the predefined morning and evening time frames (2 am–12 am or 6
pm–2 am range) and daytime values were discarded. Home BPs were calculated as the
average of 7-day qualified BP measurements in October 2007 (before the
randomization) and April 2008 (at 6-month follow-up).
3) Reduction in cardiovascular risk factors through modification of lifestyles205
The secondary endpoint was reduction of cardiovascular risk factors and lifestyle
modification, as defined in JSH 2004. BMI was calculated as body weight in
kilograms divided by the square of the height in meters (kg/m2). The questionnaires
included questions on the smoking status (yes/no), alcohol consumption (g
ethanol/day), daily exercise, and eating habits.12 Whether the patient was doing210
physical exercise equivalent to brisk walking for >30 min/day was estimated
from the responses to the following questions: (i) what sort of exercise do you do? (ii)
how often do you spend exercising in a week? (iii) how long do you spend exercising
at one time? and (iv) how long do you walk per day? The sodium reduction score was
calculated for each individual by adding one point for each of 10 sodium-reducing215
behaviors. This scoring system has been validated previously.11,16 The correlation
between sodium reduction score and sodium excretion has also been determined
previously. Age- and sex-adjusted mean 24-h sodium excretion values across quintiles
of the baseline sodium reduction score (n = 1,674) were 203, 195, 183, 180, 168
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mmol/day (P for trend <0.0001).16 Data relating to 24-h sodium excretion values are220
not reported for this study because of the limited sample size (84/132 patients, 64%).
All laboratory assays, blinded as to identification of the patient, were analyzed at
Kotobiken Medical Laboratories (Tsukuba, Japan), using standard methods.
Statistical analysis225
Our planned sample size of ≥63 patients per group had to be randomized to detect 7 or 
5 mm Hg reductions in SBP and DBP, respectively, with significance set at 5%
and power at 90%. That expected reduction in BP was same or more than the
following level improved by lifestyle modification, i.e., SBP/DBP reduction of 2.5/2.0
mm Hg by reduction in sodium intake by 77 mmol/day,17 and or SBP/DBP reduction230
of 4.4/3.6 mm Hg by weight loss of 5.1 kg.18 Also, we assumed s.d. of 8/6 mm/Hg for
SBP/DBP, on the basis of earlier reports of morning BP measurements recorded at
home in Japanese individuals with hypertension.13,19 We estimated a dropout rate of
<5% in our study, because the participants had easy access to the primary care center,
the largest community clinic in Miho village. Out of the 135 patients enrolled, 128235
completed the study and provided the required information in this trial. The
involvement of only one pharmacist could provide the higher precision in BP
measurements and the more conservative sample size calculations.
Analyses were performed according to the intention-to-treat principle.
Differences in baseline characteristics between the intervention and control groups240
were tested for significance using the independent t, the Wilcoxon rank sum, or
χ2-tests. Fisher’s exact test was used to assess differences in adherence to medication.
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We compared 6-month changes in BP levels, and clinical and lifestyle variables
between the two groups using the analysis of covariance for continuous outcomes and
multiple logistic regression model for binary outcomes. We controlled for potential245
baseline confounding by BMI (kg/m2), which was the only baseline characteristic
having a P value <0.10 for between-group comparisons, home morning SBP ≥135 
and/or DBP ≥85 mm Hg (yes or no), and antihypertensive medication use (yes or no). 
Two-tailed P values of <0.05 were considered statistically significant. In order
to minimize the hypotheses tested, we considered home morning BP and reductions in250
antihypertensive medications as the primary outcomes. All analyses were performed
using SAS software version 9.1 (SAS Institute, Cary, NC).
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Results
Study Flow and Baseline Characteristics255
Of the 236 eligible patients who met the entry criteria, 132 (56%) agreed to be
enrolled in the study (Figure 1). The proportion of those of age >60 years was
somewhat higher among those who consented to enroll than in the general pool of
eligible patients, probably more of the younger, working-age patients could not spare
the time required for the study. Of the 132 patients enrolled (66 in each group), 64260
from each group attended the 6-month follow-up; the follow-up rate in each group
was therefore 97%. Four patients did not complete the study: one was lost to
follow-up; two dropped-out, and one underwent surgery during the follow-up phase.
Throughout the trial none of the patients developed cardiovascular events that
required hospitalization. The baseline characteristics and antihypertensive medications265
were similar in the patients in the two groups (Tables 2–4). The total number of visits
to the physicians and the pharmacist during the intervention period was not
significantly different between the intervention and control groups: median
(interquartile range), 4 (4–5) vs. 4 (3–5) for visits to physicians, P = 0.42; and 5 (5–6)
vs. 4 (3–5) for visits to the pharmacist, P = 0.89, . Adherence to medication regimens270
at the baseline and 6-month follow-up time points were not significantly different
between the intervention and control groups: median (interquartile range), 100
(93–100) % vs. 100 (94–100) % at baseline, P = 0.90; and 100 (97–100) % vs. 100
(93–100) % at 6-month follow-up, P = 0.17. The total time spent per patient
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on physician consultation, including the physician–pharmacist interaction time, was275
also not significantly different between the intervention and control groups: median
(interquartile range), 17 (13–23) vs. 17 (13–23) min, P = 0.55.
Changes in antihypertensive medication regimens
During the intervention period, 20 of 64 patients (31%) in the intervention group280
discontinued antihypertensive medications or decreased the dosage of these
medications as compared to only 5 of 64 patients (8%) in the control group (P
<0.0001). There was no significant correlation between reduction in antihypertensive
medication and the age of the patient (P =0.29) or the number of antihypertensive
drugs taken (P = 0.25)(data not shown). On the other hand, 18 patients (28%) in the285
control group required additional medications or increases in dosage as compared to
only 7 patients (11%) in the intervention group (P = 0.03).With regard to changes in
antihypertensive medication regimens, drug changes were made to ensure
equivalent efficacy and not based on the classification of the drug; for example, 5 mg
amlodipine was changed to 40 mg telmisartan. The frequency of change in290
medications was not significantly different between the two groups (10 in the
intervention group vs. 9 in the control group, P = 0.73); the frequency of change in the
timing of medication administration was higher in the intervention group than in the
control group (24 vs. 9, respectively, P = 0.003).
295
BP control
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At 6 months, the mean office DBP diminished relative to the baseline in the
intervention group (SBP by 2.4 mm Hg, P =0.14, and DBP by 2.3 mm Hg, P = 0.02)
as well as in the control group (SBP by 0.9 mm Hg, P = 0.45, and DBP by 3.1 mm Hg,
P = 0.002, respectively), but the differences between the two groups in this regard300
were not significant (Table 3). The mean home morning values of SBP and DBP in
the intervention group also decreased relative to the baseline by 2.9 (P =0.02) and 3.3
mm Hg (P <0.0001), respectively. The mean decrease in home morning SBP in the
intervention group was not significantly greater than in the control group. However,
the DBP decline was significantly greater in the intervention than control groups,305
which showed a mean decrease of 2.8 mm Hg (confidence interval: –5.5 to –0.1; P =
0.04). The proportion of patients in whom the control of home morning BP was
achieved was 53% in the intervention group
and 47% in the control group, and no significant difference was noted in this regard
between the groups (P = 0.40). At the 6-month follow-up, home evening BP levels310
were similar to the baseline in the intervention group whereas they had increased
in the control group. Similar results were noted after excluding from the analysis data
relating to patients who did not receive antihypertensive medications.
Changes in cardiovascular risk factors and lifestyle modification315
At 6 months, the decrease in BMI was significantly greater in the intervention group
than in the control group (Table 4). Larger proportions of patients in the intervention
group improved their sodium reduction scores and achieved smoking cessation as
compared to the control group (P = 0.002 and P = 0.04, respectively, for the two
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lifestyle changes). As regards reduction in alcohol intake and walking >30 min/day,320
the percentages of such patients were not significantly different in the two groups (P =
0.23, P = 0.09, respectively).
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Discussion
The physician–pharmacist cooperation in this study, aimed at promoting appropriate325
changes in antihypertensive medications and dosing regimens and also in the lifestyles
of patients with mild to moderate hypertension, was shown to improve the control of
home morning DBP and reduce the use of antihypertensive medication. It also
resulted in a decrease in BMI, sodium intake, and the use of tobacco. Previous studies
have targeted patients with hypertension to improve adherence to medication regimens330
and to increase the use/dosage of antihypertensive drugs as needed. The novelty of the
present study is that it was designed to bring about reductions in BP levels through
lifestyle modification and medication changes. Specifically, the approach we adopted
was able to achieve BP control in patients even while reducing or discontinuing the
use of antihypertensive agents.335
Since morning BP readings have been regarded as a good predictor of future
cardiovascular disease,19–21 the control of morning BP used in this program is of value
for clinical practice of hypertension control. Although home BP monitoring is
described as effective in improving adherence to medications and decreasing home BP
in hypertensives,22 the present physician–pharmacist cooperative approach also340
improved home morning BP in hypertensives.
In this study, although the magnitude of reduction in home morning BP was
relatively small, same as the expected reduction level improved by lifestyle
modification, 17, 18 it may be of value, given that 3–5 mm Hg of reduction in BP is
reported to reduce potential adverse cardiac events and stroke.23 Moreover, a recent345
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study showed that lifestyle modification improved the outcome of medical treatment;
it was shown in patients with hypertension that, over a 10-year period, a reduction in
intake of salt by 1 g/day achieved BP control that was equivalent to and far more
cost-effective than the use of antihypertensive medications.24 Consequently, it has
been recommended that more emphasis be placed on lifestyle modification to control350
BP in patients undergoing treatment for hypertension. Physician–pharmacist
collaboration is a practical approach to controlling high BP, because the pharmacist
could build bridges between patients and physicians through counseling patients about
lifestyle improvement and physicians about administration of medications.
The physician–pharmacist interaction was conducted mostly over the telephone355
at the time of a visit by the patient to the physician’s office. Because the total
physician consultation time was not different between the intervention and control
groups, it was concluded that the cost of the physician–pharmacist interaction was
minimal.
Our results suggest that lifestyle modification, especially weight control and360
reduction in sodium intake, could be effective in hypertension control and allow for
reduction in antihypertensive medications. The results also showed that the proportion
of patients who quit smoking was significantly larger in the intervention group than in
the control group. Nicotine replacement treatment may enhance smoking cessation
while minimizing dropouts on account of withdrawal symptoms.365
This study has several limitations. First, counseling was conducted by one
pharmacist at a single community clinic, and blinding was not feasible. However, to
minimize the potential biases, we took the following steps: (i) ensured that the
galley, #AJH-tobari, Page 21
randomization to the two groups was carried out by an independent person; (ii)
selected home BP as the primary outcome, using BP auto-measuring devices for370
uniformity and comparability, (iii) ensured that BMI of patients was measured by
nurses who were blinded to the patient group allocation, and (iv) employed
standardized counseling scenarios and medication regimens. Second, the study
findings may be limited by potential contamination, i.e., physicians examined patients
of both the intervention and control groups. BP control may have been better in the375
intervention if such contamination of data could have been avoided. Third, 43% of
eligible patients refused to participate in the study. The proportion of individuals aged
<60 years was slightly higher among the nonparticipants than participants, probably
because younger persons were full-time workers and felt uncomfortable in devoting
their time to participate in this study. Fourth, this study took place at one outpatient380
clinic in Japan, and to our knowledge, this type of intervention has not been conducted
previously in Japan. Further studies are needed to evaluate this study with larger
populations and in various clinical settings.
In conclusion, our physician–pharmacist cooperation intervention, including
intensive counseling regarding lifestyle modifications and antihypertensive385
medication changes, improved the control of home morning BP and reduced the use of
antihypertensive medications as well as BMI, sodium intake, and the use of tobacco in
patients with mild to moderate hypertension.
390
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Figure legends
Figure 1. Flow diagram of the patient selection process.
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Figure 2. Flow chart of antihypertensive medication regimens.
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Figure 1.
Intervention
phase
236 Eligible patients approached
for informed consent
(3 months)
132 Randomized
101 Excluded
(Refused to participate)
135 Enrolled in baseline home BP
(a month run-in period)
3 Withdrew
1 Hospitalized
1 Moved out
1 Refused to participate
1 Hospitalized
1 Dropped out
1 Lost to follow-up
1 Dropped out
66 Control
64 Completed
6-month follow-up visit
66 Intervention
176 Excluded (Did not meet inclusion cliteria)
19 Age ≥80years
49 Patients with a history of cardiovascular disease
6 Rheumatoid Arthritis
67 Diabetes Mellitus requiring medication
11 Exercise restriction over 20-min brisk walking
or cycling per day
2 Hospitalized
13 Visit the clinic at irregular intervals
9 Patients judged unsuitable for the study by physician,
i.e., subjects who are difficult to get informed consent
64 Completed
6-month follow-up visit
412 Patients with hypertension
in the clinic
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Figure 2.
Yes
Mean office BP <130/85 mmHg (age <65)
<140/90 mmHg (age ≥65)
Cessation/
dosage decreases
No
Mean home BP <135/85 mmHgNo
Mean office BP ≥160/100 mmHg
or mean home BP ≥140/90 mmHg (age <65)
≥150/95 mmHg (age ≥65)
for 2 consecutive months
Addition/
dosage increases
regimen
no change
Yes Yes
(White coat hypertension)
No
Yes
No
Yes No
To control BP and/or avoid side effects,
switching medications and/or changing the
timing of medication administration were
conducted throughout the trial.
Mean office BP at last month
<130/85 mmHg (age 65)
<140/90 mmHg (age ≥65)
Mean home BP <125/80 mmHg
for 2 consecutive months
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Variables Intervention(n = 66)
Control
(n = 66)
P value for
difference
Age, mean (SD), years 61.7 (6.9) 61.6 (8.5) 0.95
Males 42 (63) 45 (68) 0.59
Family history of cardiovascular diseases 22 (33) 24 (36)
Antihypertensive medication classes 0.60
None 4 (6) 4 (6)
1 23 (35) 25 (38)
2 26 (39) 27 (41)
≥3 13 (20) 10 (15)
Categories of antihypertensive medication used
Calcium channel blockers 53 (80) 54 (82) 0.83
ACE 12 (18) 9 (14) 0.48
ARB 33 (50) 27 (41) 0.30
α-adrenergic antagonists 7 (11) 6 (9) 0.77
β-blockers 13 (20) 12 (18) 0.83
Diuretics 1 (2) 2 (3) 0.56
7.7 (8.0) 7.8 (7.4) 0.90
Statin use 15 (23) 12 (18) 0.52
No. (%) of patients unless otherwise indicated.
Table 1. Baseline characteristics of the intervention and control participants.
Duration of treatment with antihypertensive agents
mean (SD), years
ACE, Angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers.
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Control
At enrollment (baseline):
Pharmacist counseling (20 min) Same
– Orientation about the program
– Education about hypertension
– Practice in use of home BP device
Same
Explanation of results of medical examination and tests (by mail) Same
At 1-5 month:
Pharmacist counseling (15 min/month) None
– Setting individual goals of lifestyle modifications:
3–5% reduction in body weight (if BMI ≥25 kg/m2)
Reduction of daily salt intake
     Increase in vegetable intake to ≥3 portions/day
Quit smoking
Reduce alcohol intake to <23g ethanol/day
Walk at least 30 minutes/day
– Stressing the importance of individual goals
– Education about antihypertensive drug therapy
At 6 months:
Pharmacist counseling (15 min) None
– Stressing the importance of individual goals
– Counseling reports to physicians
Questions about salt intake and lifestyle Same
Explanation of results of medical examination and tests (by mail) Same
Monthly (1-6 months):
None
Home BP records to physicians and individuals Same
Pharmacists' consultation about medication at pharmacy counter Same
Physicians' formulated treatment plans
Table 2. Follow-up procedure for the intervention and control groups.
Intervention
Questions about salt intake and lifestyle
– Counseling reports to physicians with recommendations
about medication changes
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Table 3. Blood pressures and medication changes in the intervention and control groups.
n Intervention n Control
Estimated difference
between groups or
Odds Ratio at 6
months (95% CI)
*P value
for
difference
At office
SBP (95%CI)
Baseline, unadjusted mean 66 138 (135 to 141) 66 139 (136 to 142)
Change at 6 months 64 −2.4 (−5.7 to +0.8) 64 −0.9 (−4.2 to +2.3) −1.9 (−6.1 to +2.3) 0.36
DBP (95%CI)
Baseline, unadjusted mean 66 81 (80 to 83) 66 83 (81 to 85)
Change at 6 months 64 −2.3 (−4.2 to −0.3) 64 −3.1 (−5.1 to −1.2) −0.7 (−3.4 to +1.9) 0.59
At home, morning
SBP (95%CI)
Baseline, unadjusted mean 66 135 (132 to 138) 66 135 (132 to 138)
Change at 6 months 64 −2.9 (−5.5 to −0.4) 64 −1.2 (−3.8 to +1.3) −0.6 (−4.1 to +2.9) 0.73
DBP (95%CI)
Baseline, unadjusted mean 66 83 (81 to 85) 66 84 (82 to 86)
Change at 6 months 64 −3.3 (−4.8 to −1.8) 64 −1.4 (−2.9 to +0.1) −2.8 (−5.5 to −0.1) 0.04
Pulse (95%CI)
Baseline, unadjusted mean 66 68 (66 to 70) 66 66 (64 to 68)
Change at 6 months 64 −0.7 (−2.0 to +0.7) 64 +1.5 (+0.1 to +2.8) −0.6 (−3.8 to +2.6) 0.72
BP control †
Baseline 66 26 (40) 66 25 (38)
6 months 64 34 (53) 64 30 (47) 1.4 (0.6 to 3.1) 0.40
At home, evening
SBP (95%CI)
Baseline, unadjusted mean 61 125 (122 to 128) 60 126 (123 to 129)
Change at 6 months 63 −0.1 (−2.8 to +2.6) 60 +3.4 (+0.6 to +6.2) −1.9 (−6.3 to +2.5) 0.39
DBP (95%CI)
Baseline, unadjusted mean 61 75 (73 to 77) 60 77 (75 to 79)
Change at 6 months 63 −0.9 (−2.5 to +0.8) 60 +0.9 (−0.8 to +2.6) −2.0 (−5.3 to +1.3) 0.22
Pulse (95%CI)
Baseline, unadjusted mean 61 73 (71 to 76) 60 71 (69 to 74)
Change at 6 months 63 −2.4 (−4.0 to −0.8) 60 −0.9 (−2.6 to +0.7) −1.2 (−4.4 to +2.1) 0.48
Variables
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Table 3. Continued
n Intervention n Control
Estimated difference
between groups or
Odds Ratio at 6
months (95% CI)
*P value
for
difference
Any changes in antihypertensive medication, n (%) 64 47 (73) 64 31(48) 3.2 (1.5 to 6.9) 0.003
Cessation / dosage decreased, n (%) 64 20 (31) 64 5 (8) 9.8 (2.8 to 41.1) <0.0001
Calcium channel blockers 10 0
ACE 3 1
ARB 6 1
α-adrenergic antagonists 1 2
β-blockers 4 1
Diuretics 1 0
Addition / dosage increases, n (%) 64 7 (11) 64 18 (28) 0.3 (0.1 to 0.8) 0.03
Calcium channel blockers 5 5
ACE 1 0
ARB 2 6
α-adrenergic antagonists 1 2
β-blockers 3 0
Diuretics 0 7
Switching drug, n (%) 64 10 (16) 64 9 (14) 1.2 (0.4 to 3.2) 0.73
Within the same class 4 3
To the other class 6 6
Changing the timing of medication, n (%) 64 24 (38) 64 9 (14) 3.9 (1.6 to 10.1) 0.003
† Home morning BP <135/85 mmHg.
* P values are based on between-group differences adjusted for the following baseline variables: body mass index (kg/m2), home morning BP level
(SBP≥ 135 and/or DBP≥ 85 mmHg or not), and antihypertensive medication use (yes or no).
SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE, Angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers.
Variables
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Table 4. Cardiovascular risk factors and lifestyles in the intervention and control groups.
Body mass index (BMI), kg/m2
Baseline, unadjusted mean 66 25.0 (24.1 to 25.9) 66 26.1 (25.2 to 27.1)
Change at 6 months 64 −0.4 (−0.7 to −0.2) 64 0.0 (−0.2 to +0.2) −0.4 (−0.7 to −0.1) 0.008
Sodium Reduction Score, points
Baseline, unadjusted mean 66 4.4 (3.9 to 4.9) 66 4.4 (3.9 to 4.9)
Change at 6 months 64 +1.3 (+0.9 to +1.7) 64 +0.0 (−0.4 to +0.4) +1.2 (+0.5 to +2.0) 0.002
Smokers, n (%)
Baseline 66 17 (26) 66 21 (32)
6 months 64 9 (14) 64 19 (30) 0.4 (0.2 to 0.9) 0.04
Alcohol consumption>23g/day, n (%)
Baseline 66 30 (45) 66 25 (38)
6 months 64 19 (30) 64 25 (39) 0.6 (0.3 to 1.3) 0.23
Brisk walking >30 minutes/day, n (%)
Baseline 66 40 (61) 66 37 (56)
6 months 64 44 (69) 64 34 (53) 1.9 (0.9 to 4.0) 0.09
* Indicates same in Table 3.
*P value for
differenceVariables n Intervention n Control
Estimated difference
between groups or
Odds Ratio at 6 months
(95% CI)
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